Top

Published in:

01-11-2018 | Clinical Study

Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study

Authors: Stephanie R. Rice, Søren M. Bentzen, Andrew Hanna, Enid Choi, Drexell H. Boggs, Young Kwok, Jalal Hyder, Steven J. Feigenberg, William F. Regine, Graeme F. Woodworth, Howard M. Eisenberg, Cedric Yu, Terri F. Biggins, Jill S. Barnholtz-Sloan, Paul W. Sperduto, Eduardo Weltman, Minesh P. Mehta

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Purpose/Objective(s)

To compare the performance of five prognostic models [RTOG recursive partitioning analysis (RPA), Score Index for Radiosurgery in Brain Metastases (SIR), Barnholtz-Sloan–Kattan nomogram (BSKN), diagnosis-specific Graded Prognostic Assessment (dsGPA), and Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)] against actual survival in patients with brain metastases treated with SRS +/− WBRT.

Materials/Methods

100 consecutive patients treated with SRS +/− WBRT between January 2006 and July 2012 were retrospectively analyzed. Patients were binned according to 33 percentiles of the predicted survival distribution for the BSKN and dsGPA models to compare with LungmolGPA, RPA and SIR. Pearson’s correlation coefficients between predicted and observed survival were estimated to quantify the proportion of variance in observed survival.

Results

Median survival for the entire cohort was 13.5 months, with predicted vs actual MS by BSKN, SIR, dsGPA, RPA, adenocarcinoma Lung-molGPA, and nonadenocarcinoma Lung-molGPA was 3.8 vs 15.6 months, 7 vs 13.5 months, 9.4 vs 13.5 months, 10.3 vs 13.5 months, 13.7 vs 13.7 months, and 9.8 vs 9.7 months, respectively. The BSKN model and adenocarcinoma LungmolGPA created three groups with a statistically significantly different MS (p = 0.002 and p = 0.01, respectively).

Conclusion

All models under-predicted MS and only the BSKN and Lung-molGPA model stratified patients into three risk groups with statistically significant actual MS. The prognostic groupings of the adenocarcinoma Lung-molGPA group was the best predictor of MS, and showed that we are making improvements in our prognostic ability by utilizing molecular information that is much more widely available in the current treatment era.

American Brain Tumor Association (2016) Metastatic brain tumors. Am Brain Tumor Assoc. https://doi.org/10.1002/1097-0142(19810215)47 CrossRef

Ahluwalia M, Vogelbaum M, Chao S, Mehta M (2014) Brain metastasis and treatment. F1000Prime Rep 6:114. https://doi.org/10.12703/P6-114 CrossRefPubMedPubMedCentral

Venur AV, Ahluwalia MS (2015) Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chinese Clin Oncol 4(2):1–7. https://doi.org/10.3978/j.issn.2304-3865.2015.06.01 CrossRef

Johung KL, Yeh N, Desai NB et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129. https://doi.org/10.1200/JCO.2015.62.0138 CrossRefPubMed

Rusthoven CG, Doebele RC (2016) Management of brain Metastases in ALK-positive non-small-cell lung cancer. J Clin Oncol 34(24):2814–2819. https://doi.org/10.1200/JCO.2016.67.2410 CrossRefPubMed

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Li J, Bentzen SM, Li J, Renschler M, Mehta MP (2008) Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71(1):64–70. https://doi.org/10.1016/j.ijrobp.2007.09.059 CrossRefPubMed

10.

Li J, Bentzen SM, Renschler M, Mehta MP (2007) Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25(10):1260–1266. https://doi.org/10.1200/JCO.2006.09.2536 CrossRefPubMed

11.

Golden DW, Lamborn KR, McDermott MW et al (2008) Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg 109:77–86. https://doi.org/10.3171/JNS/2008/109/12/S13 CrossRefPubMed

12.

Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751. https://doi.org/10.1016/S0360-3016(96)00619-0 CrossRefPubMed

13.

Weltman E, Salvajoli JV, Brandt RA et al (2000) Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 46(5):1155–1161. https://doi.org/10.1016/S0360-3016(99)00549-0 CrossRefPubMed

14.

Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients With newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661. https://doi.org/10.1016/j.ijrobp.2009.08.025 CrossRefPubMed

15.

Barnholtz-Sloan JS, Yu C, Sloan AE et al (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 14(7):910–918. https://doi.org/10.1093/neuonc/nos087 CrossRefPubMedPubMedCentral

16.

Sperduto PW, Yang TJ, Beal K et al (2016) The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys 96:406–413. https://doi.org/10.1016/j.ijrobp.2016.06.006 CrossRefPubMedPubMedCentral

17.

Sperduto PW, Jiang W, Brown PD et al (2017) Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812–816. https://doi.org/10.1016/j.ijrobp.2017.06.2454 CrossRefPubMedPubMedCentral

18.

Sperduto PW, Jiang W, Brown PD et al (2017) The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 98:1069–1077. https://doi.org/10.1016/j.ijrobp.2017.03.030 CrossRefPubMedPubMedCentral

19.

Sperduto PW, Yang TJ, Beal K et al (2017) Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 3(6):827. https://doi.org/10.1001/jamaoncol.2016.3834 CrossRefPubMed

20.

White N, Reid F, Harris A, Harries P, Stone P (2016) A systematic review of predictions of survival in palliative care: how accurate are clinicians and who are the experts? PLoS ONE 11(8):e0161407. https://doi.org/10.1371/journal.pone.0161407 CrossRefPubMedPubMedCentral

21.

Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198. https://doi.org/10.1136/bmj.327.7408.195 CrossRefPubMedPubMedCentral

22.

Nieder C, Mehta MP (2009) Prognostic indices for brain metastases—usefulness and challenges. Radiat Oncol 4(1):10. https://doi.org/10.1186/1748-717X-4-10 CrossRefPubMedPubMedCentral

23.

IBM SPSS Statistics for Windows. No Title. 2011

24.

Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. JAMA 316(4):401. https://doi.org/10.1001/jama.2016.9839 CrossRefPubMedPubMedCentral

25.

Sperduto PW, Yang TJ, Beal K et al (2017) Estimating survival in patients with lung cancer and brain metastases. JAMA Oncol 3(6):827. https://doi.org/10.1001/jamaoncol.2016.3834 CrossRefPubMed

26.

Kondziolka D, Parry PV, Lunsford LD et al (2014) The accuracy of predicting survival in individual patients with cancer. J Neurosurg 120(1):24–30. https://doi.org/10.3171/2013.9.JNS13788 CrossRefPubMed

Title: Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study
Authors: Stephanie R. Rice
Søren M. Bentzen
Andrew Hanna
Enid Choi
Drexell H. Boggs
Young Kwok
Jalal Hyder
Steven J. Feigenberg
William F. Regine
Graeme F. Woodworth
Howard M. Eisenberg
Cedric Yu
Terri F. Biggins
Jill S. Barnholtz-Sloan
Paul W. Sperduto
Eduardo Weltman
Minesh P. Mehta
Publication date: 01-11-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2958-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study

Abstract

Purpose/Objective(s)

Materials/Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose/Objective(s)

Materials/Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Palliative care education in U.S. adult neuro-oncology fellowship programs

Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme

Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas

Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway

Correction to: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts